Secretome, Exosomes, and Conditioned Media

What "cell-free" therapy actually means

The therapeutic effect of mesenchymal stromal cells is increasingly understood to come not from the cells themselves surviving and differentiating, but from the molecules they secrete — cytokines, growth factors, extracellular vesicles including exosomes, and microRNAs. This "secretome" is the paracrine signal library.

Conditioned media (CM) is what remains after MSCs have been cultured in growth medium and then filtered out: the medium contains everything the cells were secreting, minus the cells. Concentrated CM, further-processed exosome preparations, and defined "secretome cocktails" are all versions of this idea.

The pitch is straightforward — if the effect is paracrine, deliver the paracrine payload without the manufacturing complexity, cold-chain fragility, or regulatory burden of living cells. The reality is more complicated.

Why regulators are watching this space closely

Because secretome and exosome products can be positioned as "not stem cells," some marketers have used them to sidestep regulatory frameworks that apply to cell therapies. The FDA has issued repeated warning letters to U.S. clinics selling exosome products without regulatory clearance, including several enforcement actions triggered by adverse events. INVIMA has similarly cautioned that cell-derived products are not exempt from oversight simply because they are cell-free.

What this means practically: a clinic advertising "exosome infusion" or "secretome therapy" is not offering a fundamentally different regulatory category. They are offering a cell-derived product, and the same questions about manufacturing, quality control, and evidence apply.

What the evidence supports

Preclinical evidence for MSC-derived exosomes and conditioned media is substantial — in cell culture and animal models, they replicate many of the anti-inflammatory and pro-regenerative effects attributed to cell therapy. Early human trials exist for wound healing, hair loss, and some inflammatory conditions.

What is missing: adequately powered controlled trials showing that a specific commercial exosome or CM product produces meaningful clinical outcomes at a defined dose across multiple centers. That evidence tier does not yet exist for most indications.

The characterization problem

"Exosomes" from vendor A are not necessarily comparable to "exosomes" from vendor B. Particle counts, protein content, membrane markers, and cargo vary based on source cells, culture conditions, isolation method, and processing. Without standardized characterization, cross-study comparison is difficult, and consistent clinical outcomes are hard to expect.